Hansoh Pharma Unveils New Biologics R&D Center in Shanghai to Accelerate Innovation and Industrialization

SHANGHAI, Jan. 29, 2021 /PRNewswire/ -- On January 28, the launch ceremony of the biologics R&D center of Shanghai Hansoh Biomedical Co., Ltd., a subsidiary of Hansoh Pharma, was successfully held at Jiechang Technology Park in Pudong New Area, Shanghai. The inauguration of this R&D center holds profound significance for Hansoh Pharma’s further deepening of its biologics research and development and industrialization layout, marking that the company’s innovative biologic drug R&D has entered a fast lane and ushering in a new chapter of innovation-driven R&D and the transformation and upgrading of its product portfolio.

Unveiling Ceremony of the Biologics R&D Center

China’s pharmaceutical industry is at a critical juncture of structural adjustment and transformational upgrading. As a strategic emerging industry in China, the biopharmaceutical sector plays a significant role in promoting industrial optimization and upgrading, fostering innovation-driven growth, and further meeting the people’s growing demands for healthcare services. With 25 years of development history as a domestic pharmaceutical enterprise, Hansoh Pharma has long focused on biopharmaceuticals and made strategic investments in this area. Keeping pace with the forefront of international pharmaceutical innovation, the company established its Biologics R&D Center in 2016 to leverage cutting-edge global technologies for the research, development, and industrialization of innovative biologics. Its product pipeline covers therapeutic areas including oncology, autoimmune diseases, and metabolic disorders. The company has built an advanced biologics R&D platform compliant with Good Manufacturing Practice (GMP) standards, and its first biologic drug has been approved for clinical trials. The newly inaugurated Biologics R&D Center spans 6,300 square meters and is equipped with specialized laboratories for cell line development, cell culture process development, protein purification, formulation development, and quality analysis.

Biologics R&D Center Building

Focus on innovation is the core driving force behind Hansoh Pharma’s development. By continuously increasing its investment in research and development (R&D) year after year, the company has established a comprehensive R&D platform and mastered a portfolio of proprietary technologies. It has set up R&D centers in Shanghai and Lianyungang, created multiple national-level R&D institutions, and ranked among the top three industrial enterprises in China for pharmaceutical R&D product pipelines for consecutive years. Hansoh Pharma prioritizes the development of new products in therapeutic areas such as central nervous system (CNS) disorders, oncology, anti-infectives, and diabetes. To date, it has launched four Class 1 innovative drugs, with over 100 projects in the pipeline, including five innovative drugs that have entered Phase II clinical trials or later stages. With the inauguration of its biologics R&D center, Hansoh Pharma will leverage Shanghai’s expansive open-development platform and its diverse advantages in policy, talent, and resources to accelerate innovative growth and fulfill its corporate mission of “excelling in national pharmaceuticals and strengthening Chinese innovation.”